Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Next Previous
Trial Profile

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramucirumab (Primary) ; Cyclophosphamide; Vinorelbine
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms CAMPFIRE
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 22 Nov 2024 Planned End Date changed from 31 Oct 2024 to 1 Oct 2025.
  • 04 Jun 2024 Planned End Date changed from 30 Apr 2024 to 31 Oct 2024.
  • 04 Jun 2024 Planned primary completion date changed from 30 Apr 2024 to 11 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top